LEIDOS BIOMEDICAL RESEARCH, INC.
LEAD OPTIMIZATION OF A LONG NON-CODING RNA (LNCRNA) AS A POTENTIAL LIPID- AND GLUCOSE-LOWERING THERAPEUTIC
LEAD OPTIMIZATION OF A LONG NON-CODING RNA (LNCRNA) AS A POTENTIAL LIPID- AND GLUCOSE-LOWERING THERAPEUTIC is a funding opportunity from LEIDOS BIOMEDICAL RESEARCH, INC., up to 921875, closing September 14, 2030.
Sep 14, 2030
(1506d left)Overview
The contractor(s) will be responsible to perform synthesis of lead RNA candidates, conducting potency assay development to optimize and downslect RNA leads, to conduct exploratory toxicity studies and DMPK to assess the safety of the leads, and in vivo efficacy studies as a go/no go miletone.